Assay News and Research

RSS

Thermo Fisher Scientific announces opening of Molecular Biology Center of Excellence in Lithuania

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its Molecular Biology Center of Excellence in Vilnius, Lithuania.

From Thermo Fisher Scientific Inc. 20 Sep 2012

TECHLAB to utilize Dynex's Gold SmartKit packaging for ELISA product line

Dynex Technologies, Inc. announced today it has finalized a supply agreement with TECHLAB, Inc. (Blacksburg, VA), allowing TECHLAB to utilize Dynex's Gold SmartKit packaging for their ELISA product line.

20 Sep 2012

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting.

19 Sep 2012

ProImmune launches ProStorm in vitro cytokine release assay

ProImmune Ltd., a leader in services for understanding immune responses, announced today the commercial launch of ProStorm, an in vitro cytokine release assay, which can help assess the likelihood of first infusion reactions to novel therapeutics.

18 Sep 2012

No association between XMRV/pMLV and chronic fatigue syndrome

The causes of chronic fatigue syndrome (CFS) have long eluded scientists. In 2009, a paper in the journal Science linked the syndrome-sometimes called myalgic encephalomyelitis (ME)-to infection with a mouse retrovirus called XMRV (xenotropic murine leukemia virus (MLV)-related virus).

18 Sep 2012

VTT, GE Healthcare enter collaboration for AD research

Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer's disease months or even years before the first symptoms of the disease occur. The goal of the new collaboration between VTT and GE Healthcare is to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.

17 Sep 2012

Novel serum assay measures calcification risk

Researchers have devised a nephelometer-based assay that measures the risk for calcification in serum samples.

12 Sep 2012

PrimeraDx’s ICEPlex system and C. difficile detection assay receive CE mark

PrimeraDx, a molecular diagnostics company, announced today that the ICEPlex system, a quantitative multiplex PCR system, and their C. difficile detection assay both received the CE mark.

12 Sep 2012

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance of breast cancer to a well-regarded and widely used cancer therapy.

12 Sep 2012

Study discovers pathways that govern instability of GAA/TTC repeats

A study of more than 6,000 genes in a common species of yeast has identified the pathways that govern the instability of GAA/TTC repeats. In humans, the expansions of these repeats is known to inactivate a gene - FXN - which leads to Friedreich's ataxia, a neurodegenerative disease that is currently incurable. In yeast, long repeats also destabilize the genome, manifested by the breakage of chromosomes.

11 Sep 2012

NIH awards Immunetics $3.7M SBIR contract for Babesia infection blood screening test

Immunetics, Inc., has received a $3.7 million, two year SBIR contract from the National Heart, Lung and Blood Institute, an agency of the National Institutes of Health (NIH), to support clinical trials of a new blood screening test for Babesia infection.

10 Sep 2012

Simple assay to improve treatment for idiopathic membranous nephropathy

Simple blood tests could help physicians decide which patients with a particular autoimmune kidney disease can forgo potentially toxic medications and which need to be treated, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

7 Sep 2012

Test to identify potentially deadly calcium deposits in tissues and blood vessels

A new test could help identify and treat individuals at risk of developing potentially deadly calcium deposits in their tissues and blood vessels, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. Heart disease is the number one killer of patients with chronic kidney disease (CKD), and vascular calcification is thought to play a major role.

7 Sep 2012

Therapeutic targets for pemphigus vulgaris discovered

Researchers have identified the primary target of the autoantibodies found in the serum of patients with the blistering skin disorder pemphigus vulgaris.

7 Sep 2012

Drug discovery solutions from SPT Labtech to be demonstrated at MipTech

SPT Labtech will be offering delegates at MipTec 2012 (24th-27th September, Basel, Switzerland) the opportunity to experience their innovative automated solutions for effortless drug discovery first-hand.

From SPT Labtech 7 Sep 2012

University of Rhode Island engineers develop new blood-testing technology

A team of engineers and students at the University of Rhode Island has developed an advanced blood-testing technology that incorporates a smartphone application, a hand-held biosensor and a credit card-sized cartridge to provide rapid, accurate biological analysis and wireless communication of test results.

7 Sep 2012

The Institute of Cancer Research, CRT and Astex to discover and develop novel drug candidates

Astex Pharmaceuticals, Inc, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

7 Sep 2012

BioReliance introduces Reconstructed Skin Micronucleus Assay to detect DNA damage

Sigma-Aldrich Corporation today announced that its recent acquisition, BioReliance, the biopharma and early development services business under SAFC, will introduce a new assay to detect DNA damage from products with dermal routes of exposure. The Reconstructed Skin Micronucleus (RSMN) Assay represents the first commercial offering of a Genetic Toxicology assay using three-dimensional tissue models.

5 Sep 2012

Study evaluates prognostic utility of novel biomarkers of cardiovascular stress

Critical Diagnostics announced today, Circulation, an American Heart Association Journal, released online the first study evaluating the power of ST2 to predict development of heart failure and other adverse outcomes in the general population titled, "Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study".

5 Sep 2012

PRISM technique as accurate as ELISAs in identifying proteins within biological samples

Combining two well-established analytic techniques and adding a twist identifies proteins from blood with as much accuracy and sensitivity as the antibody-based tests used clinically, researchers report this week in Proceedings of the National Academy of Sciences Early Edition online.

4 Sep 2012

Assay News and Research

Thermo Fisher Scientific announces opening of Molecular Biology Center of Excellence in Lithuania

TECHLAB to utilize Dynex's Gold SmartKit packaging for ELISA product line

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

ProImmune launches ProStorm in vitro cytokine release assay

No association between XMRV/pMLV and chronic fatigue syndrome

VTT, GE Healthcare enter collaboration for AD research

Novel serum assay measures calcification risk

PrimeraDx’s ICEPlex system and C. difficile detection assay receive CE mark

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

Study discovers pathways that govern instability of GAA/TTC repeats

NIH awards Immunetics $3.7M SBIR contract for Babesia infection blood screening test

Simple assay to improve treatment for idiopathic membranous nephropathy

Test to identify potentially deadly calcium deposits in tissues and blood vessels

Therapeutic targets for pemphigus vulgaris discovered

Drug discovery solutions from SPT Labtech to be demonstrated at MipTech

University of Rhode Island engineers develop new blood-testing technology

The Institute of Cancer Research, CRT and Astex to discover and develop novel drug candidates

BioReliance introduces Reconstructed Skin Micronucleus Assay to detect DNA damage

Study evaluates prognostic utility of novel biomarkers of cardiovascular stress

PRISM technique as accurate as ELISAs in identifying proteins within biological samples

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News